Cerenis Therapeutics, an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases and new HDL-based vectors for the targeted drug delivery in the oncology field has announced the appointment of Barbara Yanni to its board of directors as an independent director.
Jean-Louis Dasseux, founder and CEO of Cerenis, said: "We are proud to welcome Barbara Yanni to Cerenis' board of directors. This is a unique opportunity for us, as Barbara is highly regarded in the pharmaceutical industry as a business and financial expert with deep experience as a senior business development executive."
"Her endeavors also allowed Merck to be recognized as the 'best biopharma partner'. Without any doubt we will greatly benefit from her superb interpersonal skills and background to help Cerenis in future strategy and deal negotiations as we better understand large and small potential partners."
Yanni is currently an Independent Director of three other clinical-stage biotech companies: Trevena, Vaccinex and Symic Bio. She has more than 30 years of experience in pharma and biotechnology.
As Chief Licensing Officer at Merck & Co., she has built strong relationships within the pharmaceutical, biotech and venture community. She oversaw successful strategic collaborations for 33 clinical and/or commercial compounds, 13 preclinical compounds and more than 100 compounds at the discovery, formulation or research technology stage.
Prior to her leadership roles in business development at Merck, Yanni conducted financial analyses of business development opportunities and employee benefits and devised and implemented strategies to minimize Merck’s corporate taxes.
Yanni holds an AB in Physics from Wellesley College, an LLM in Taxation from New York University and a JD from Stanford Law School.
